Keros Therapeutics
KROS
81 hedge funds and large institutions have $1.13B invested in Keros Therapeutics in 2020 Q4 according to their latest regulatory filings, with 36 funds opening new positions, 34 increasing their positions, 6 reducing their positions, and 4 closing their positions.
800% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 4
467% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 6
148% more capital invested
Capital invested by funds: $455M → $1.13B (+$675M)
65% more funds holding
Funds holding: 49 → 81 (+32)
20.99% more ownership
Funds ownership: 58.41% → 79.39% (+21%)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$53.9M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$35.1M |
| 3 |
BlackRock
New York
|
+$34.3M |
| 4 |
Alkeon Capital Management
New York
|
+$31M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$21.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$72.5M |
| 2 |
CA
CHI Advisors
New York
|
-$8.55M |
| 3 |
FI
Fosun International
Hong Kong,
China
|
-$3.22M |
| 4 |
TC
Telemus Capital
Southfield,
Michigan
|
-$775K |
| 5 |
Renaissance Technologies
New York
|
-$479K |
KROS Hedge Fund Activity: Q4 2020 in Review
81 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Keros Therapeutics (KROS) for Q4 2020, worth a combined $1.13B — up 148% from $455M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new KROS positions and 4 closed out — a net gain of 32 holders — while 34 added to existing stakes and 6 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $53.9M. The largest seller was Logos Global Management, cutting an estimated $72.5M.
- 81 institutional investors held Keros Therapeutics (KROS) as of Q4 2020, up from 49 in Q3 2020.
- Funds reported $1.13B of Keros Therapeutics stock for Q4 2020, up 148% quarter-over-quarter.
- 36 funds opened new Keros Therapeutics positions in Q4 2020 and 4 closed out, a net change of +32 holders.
- The largest Keros Therapeutics buyer in Q4 2020 was Fidelity Investments, an estimated $53.9M added.
- The largest Keros Therapeutics seller in Q4 2020 was Logos Global Management, an estimated $72.5M sold.
Based on aggregated 13F filings for Q4 2020.